NCT06658964 - Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2024

Primary Completion Date

December 10, 2024

Study Completion Date

March 21, 2025

Conditions

ADPKD (autosomal Dominant Polycystic Kidney Disease)

Interventions

DRUG

Cohort 1: JMKX003142 and itraconazole

"JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD"

DRUG

Cohort 2: JMKX003142 and rifampicin

"JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD"